Scheiter, Alexander http://orcid.org/0000-0001-6734-261X
Hierl, Frederik
Lüke, Florian
Keil, Felix
Heudobler, Daniel
Einhell, Sabine
Klier-Richter, Margit
Konstandin, Nikola P.
Weber, Florian
Scheiter, Andrea
Kandulski, Arne
Schlosser, Sophie
Cosma, Lidia-Sabina
Tews, Hauke
Weiss, Andreas R. R.
Grube, Matthias
Bumes, Elisabeth
Hau, Peter
Proescholdt, Martin
Steger, Felix
Troeger, Anja
Haferkamp, Sebastian
Reibenspies, Lucas E.
Schnabel, Marco J.
Schulz, Christian
Drexler, Konstantin
Hatzipanagiotou, Maria E.
Seitz, Stephan
Klinkhammer-Schalke, Monika
Unberath, Philipp
Calvisi, Diego F. http://orcid.org/0000-0002-6038-8567
Pukrop, Tobias
Dietmaier, Wolfgang
Evert, Matthias
Utpatel, Kirsten
Article History
Received: 22 September 2022
Revised: 5 December 2022
Accepted: 12 December 2022
First Online: 26 December 2022
Ethics approval and consent to participate
: The prospective observational study of the molecular tumour board MTB of the Comprehensive Cancer Center Ostbayern (CCCO) was conducted following the Declaration of Helsinki and approved by the Ethics Committee of the University of Regensburg (protocol code 20-1682-101). All included patients gave their written consent to participate in this observational study.
: Written consent for publication was obtained from all patients included in the MTB observational study.
: The authors declare the following competing interests: Alexander Scheiter: Travel/expenses: Roche. StS: Honoraria: AstraZeneca, lovis, GE, Gilead, GSK, MSD, Novartis, Pfizer, Roche, and Lilly. MJS: Advisory board: Bayer, Bristol Myers Squibb, Ipsen, Merck & Co, Pfizer. Honoraria: Bayer, Bristol Myers Squibb, GlaxoSmithKline, Ipsen, Medac, Merck, MSD, Pfizer. Travel/accommodation/expenses: Apogepha, Janssen, Ipsen, Pfizer. Institutional grants/contracts: Ipsen, Janssen, AstraZeneca, QED Therapeutics Inc. SH: Honoraria: BMS, Pierre Fabre, MSD, Novartis. KU: Advisory Board: BMS. Lecture fees: Roche.